10-Q: HeartBeam Q3 2025: Cash Shortfall, FDA Progress

HeartBeam, Inc. reports continued losses and significant cash burn, raising going concern doubts, despite FDA clearance for its HeartBeam System and progress on 12L ECG synthesis software.

Summary

• HeartBeam, Inc. reported a net loss of $15.7 million for the nine months ended September 30, 2025, an increase from $14.5 million in the prior year period.
• Cash and cash equivalents stood at $1.9 million as of September 30, 2025, down from $2.4 million at December 31, 2024.
• Management believes existing liquidity is insufficient to fund operations for the next twelve months, raising substantial doubt about the company's ability to continue as a going concern.
• The HeartBeam System, a patient-held ECG device, received FDA clearance on December 13, 2024.
• A 510(k) notification was filed in January 2025 for software algorithms that synthesize a 12L ECG from the HeartBeam System.
• The VALID-ECG Study results, presented in April 2025, showed a 93.4% overall diagnostic agreement for HeartBeam's synthesized 12L ECG compared to a standard 12L ECG for arrhythmia assessment.
• A strategic collaboration with AccurKardia was announced in April 2025 to potentially add automated ECG interpretation to HeartBeam's product.
• The company has an At-the-Market (ATM) sales agreement with approximately $15.5 million available for issuance as of the financial statement issuance date.
• Research and development expenses increased by 24% to $10.1 million for the nine months ended September 30, 2025, compared to $8.2 million in the prior year.
• General and administrative expenses decreased by 15% to $5.7 million for the nine months ended September 30, 2025, from $6.8 million in the prior year.
• Net proceeds of approximately $10.3 million were raised from a public offering in February 2025.
• HeartBeam holds a total of 24 issued patents worldwide, including 16 U.S. patents, with additional applications pending.

Sentiment

Score: 3

Explanation: While there are positive developments in product innovation, FDA clearances, and intellectual property expansion, these are heavily overshadowed by the severe liquidity issues and an explicit 'going concern' warning. The company's financial health is precarious, with significant uncertainty regarding its ability to secure necessary funding for continued operations, indicating a high-risk profile.

Positives

• FDA clearance was granted for the initial patient-held ECG device, the HeartBeam System, on December 13, 2024.
• Positive results from the VALID-ECG Study demonstrated a 93.4% overall diagnostic agreement for HeartBeam's synthesized 12L ECG software for arrhythmia assessment.
• A strategic collaboration with AccurKardia is expected to enhance commercial offerings, expedite product development, and reduce costs and timelines by adding automated ECG interpretation.
• The company has significantly expanded its intellectual property portfolio, securing seven new U.S. patents in 2025 and receiving a Notice of Allowance for an additional U.S. patent application, bringing the total to 24 issued patents worldwide.
• HeartBeam's AI algorithm demonstrated high accuracy in classifying atrial fibrillation, atrial flutter, and sinus rhythm, performing equally well on the HeartBeam System compared to standard 12L ECGs.
• Successfully raised approximately $10.3 million in net proceeds from a public stock offering in February 2025.
• General and administrative expenses decreased by 15% for the nine months ended September 30, 2025, reflecting cost reduction efforts.

Negatives

• The company has incurred losses and negative cash flows from operations every year since inception.
• Cash and cash equivalents of $1.9 million as of September 30, 2025, are deemed insufficient to fund operations for the next twelve months.
• There is substantial doubt regarding the company's ability to continue as a going concern.
• Net loss increased to $15.7 million for the nine months ended September 30, 2025, from $14.5 million in the comparable prior year period.
• Interest income decreased significantly by 71% for the nine months ended September 30, 2025, compared to the prior year.
• No material commercial revenue is expected in 2025.
• Management cannot provide assurance that necessary financing or strategic relationships will be available on acceptable terms, or at all.

Risks

• Substantial doubt exists regarding the company's ability to continue as a going concern due to insufficient liquidity to fund operations for the next twelve months.
• Continued operations are dependent on the ability to raise additional capital through equity and/or debt financings or strategic relationships.
• There is no assurance that such financing or strategic relationships will be available on acceptable terms, or at all, which could have a material adverse effect on the company and its financial statements.
• The company faces risks similar to those of early-stage companies, including dependence on key individuals and product candidates.
• Difficulties are inherent in the development of a commercial market for its products.
• The company faces competition from larger companies, other technology companies, and other technologies.
• Future FDA clearances for Class II medical devices, such as the 12L ECG synthesis software, are expected to require clinical data.

Future Outlook

The company expects no material commercial revenue in 2025. Its continued operations are dependent on raising additional capital through various potential sources like equity/debt financings or strategic relationships. Management believes that achieving critical clinical and regulatory milestones will provide the ability to raise this capital. The company is focused on commercial readiness activities in anticipation of a commercial launch once it receives FDA clearance for its 12L synthesis software, with an estimated clearance date of December 31, 2025, for certain performance-based stock options. Deep learning algorithms are also expected to be utilized for future FDA submissions to enhance product offerings.

Management Comments

• "Management believes the continued achievement of these milestones will provide the Company the ability to raise additional capital."
• "Management can provide no assurance that such financing or strategic relationships will be available on acceptable terms, or at all, which if not consummated would likely have a material adverse effect on the Company and its financial statements."
• "We intend to strike a balance of managing our headcount in line with cash resources, while also, at the appropriate time, hiring or engaging additional full-time professionals, employees, and / or consultants in alignment with our growth strategy."

Industry Context

HeartBeam operates in the rapidly evolving ambulatory cardiac monitoring sector, aiming to disrupt traditional cardiac care with its proprietary 3D 3-Lead ECG technology and 12-Lead ECG synthesis software. This positions the company against established hospital-based ECG systems and other portable monitoring solutions. The strategic collaboration with AccurKardia for automated ECG interpretation and an active AI program highlight a focus on leveraging advanced technologies to enhance diagnostic capabilities and gain a competitive edge. The company also aims to play a central role in high-risk Coronary Artery Disease (CAD) monitoring, indicating a broader strategic vision within cardiovascular health.

Comparison to Industry Standards

• HeartBeam's proprietary 3D ECG technology has demonstrated diagnostic capability equal or superior to traditional hospital-based ECG systems in early studies.
• The VALID-ECG Study showed a 93.4% overall diagnostic agreement between HeartBeam's synthesized 12L ECG and a simultaneously collected standard 12L ECG for arrhythmia assessment.
• HeartBeam's deep learning algorithms performed equally well on the HeartBeam System compared to standard 12L ECGs in classifying atrial fibrillation, atrial flutter, and sinus rhythm.
• The company's unique portable form-factor aims to make high-fidelity insights easily accessible wherever patients are, offering an advantage over standard 12L ECGs typically confined to healthcare settings.

Corporate Governance

Related Party Transactions

• Accounts payable included $10 thousand (September 30, 2025) and $5 thousand (December 31, 2024) related to related parties.
• A consulting agreement with an independent Board of Directors member, initiated in April 2024, involves a payment of $5,000 per month and a grant of 70,000 options vesting over 36 months. The company recognized $25,700 in expenses for this service during the three months ended September 30, 2025 and 2024, and $76,600 and $50,200 for the nine months ended September 30, 2025 and 2024, respectively, including stock-based compensation.

Stakeholder Impact

• Shareholders face significant risk of value erosion due to the explicit 'going concern' warning and persistent losses. Potential for substantial dilution from future equity capital raises.
• Employees are impacted by the company's need to manage headcount in line with cash resources, though stock-based compensation remains a component of remuneration.
• Future customers stand to benefit from innovative cardiac monitoring solutions if the company successfully commercializes its technology.
• Creditors face increased risk due to the company's precarious financial position and limited cash reserves.

Next Steps

• Obtain FDA clearance for the 12L synthesis software algorithms (510(k) notification filed in January 2025).
• Proceed with the anticipated commercial launch of the ambulatory device that synthesizes a 12L ECG for arrhythmia assessment.
• Continue the early access program to gather valuable feedback on user experience, workflow, and system functionality.
• Further develop the active AI program and utilize deep learning algorithms for future FDA submissions to enhance product offerings.
• Raise additional capital through equity and/or debt financings or strategic relationships to fund operations.
• Manage headcount in line with cash resources and strategically hire or engage additional full-time professionals, employees, and/or consultants to support growth.

Key Dates

Recommendation

The explicit 'going concern' warning, coupled with persistent net losses, negative operating cash flow, and rapidly dwindling cash reserves, indicates severe financial distress. While product development and FDA clearances are positive, the company's ability to fund operations for the next 12 months is in substantial doubt. The need for significant additional capital, with no assurance of availability on acceptable terms, makes the stock highly speculative and vulnerable to further declines. Existing shareholders face substantial dilution risk, and new investors would be entering a financially precarious situation. A 'sell' recommendation is warranted given the high financial risk and uncertainty.

Keywords

Cardiac technology, ECG, Electrocardiogram, HeartBeam System, FDA clearance, Arrhythmia, Myocardial Infarction, Coronary Artery Disease, AI, Deep Learning, Medical device, Telehealth, Ambulatory monitoring, 12-Lead ECG, Going concern, Capital raise, Stock offering, Patents